AI Healthcare Stocks With Real Adoption Milestones Investors Can Watch

AI healthcare sits at the crossroads of two powerful forces. Health systems worldwide are under pressure from inflation, tight budgets, and ageing populations, while investors are watching central banks, bond yields, and energy prices closely. The Transformative AI Healthcare Stocks screener focuses on companies using artificial intelligence to improve diagnostics, treatment decisions, and research productivity. That links into themes like efficiency, cost control, and better use of data, which matter when policy and financing conditions are in flux. In this article, you will see three stocks from the screener that help turn this big idea into specific opportunities to research further.

Telescope Innovations (CNSX:TELI)

Overview: Telescope Innovations develops chemical technology, tools, and processes that help pharmaceutical, critical minerals, and chemical companies run and analyze complex reactions more efficiently, including its DIRECTINJECT-LC hardware and software platform. It also earns revenue from intellectual property and contract research, supported by collaborations with Pfizer, Standard Lithium, and AGI Group on automation and AI-ready reactor technology.

Operations: Telescope Innovations generates about CA$7.3 million in revenue entirely from chemicals, with most sales from the United States alongside smaller contributions from Canada and Europe.

Market Cap: CA$34.8 million

Telescope Innovations operates at the intersection of AI, automation, and lab-scale chemistry, which has attracted the interest of large partners such as Pfizer and a major global pharmaceutical company that recently agreed to deploy its Self-Driving Lab in Europe. Recent results show losses and a return on equity in negative territory. In addition, less than one year of cash runway makes funding an important risk to monitor. Revenue is already in the low single digit millions and the Self-Driving Lab is being rolled out across multiple global sites. These developments provide specific milestones investors can watch to assess whether this small cap converts commercial interest into a more durable business model over time.

Telescope Innovations sits at the crossroads of AI chemistry and tight funding. Before you decide how that trade off could play out, review the detailed Telescope Innovations financial health report

Profound Medical (TSX:PRN)

Overview: Profound Medical develops AI-powered, MRI-guided systems that allow doctors to destroy diseased tissue inside the body without surgical incisions, led by its TULSA-PRO platform for precisely targeting prostate tissue. The company also offers Sonalleve, which uses MRI and focused ultrasound to treat conditions such as uterine fibroids and painful bone metastases.

Operations: Profound Medical generates about US$18.8 million in revenue from medical technology, with around US$12.3 million from the United States, US$5.8 million from Canada, and a smaller contribution from Germany.

Market Cap: CA$373.2 million

Profound Medical operates in the field of AI-guided, incision-free cancer care, and the latest CAPTAIN trial data released on 24 July 2026 adds a quality-of-life angle that many prostate treatments may not address to the same extent. Early results indicate TULSA procedures preserved penile length at 1 month compared with robotic surgery, while larger safety and cancer control outcomes are expected to be reported over the next few years. Revenue guidance of about US$25 million for 2026 provides a reference point for how quickly hospitals may be adopting the technology, even as the company remains loss-making and reliant on higher risk borrowing. For investors weighing a premium P/S ratio and recent dilution against growth forecasts and growing clinical evidence, Profound Medical may warrant further research.

Profound Medical sits where AI, MRI guidance, and quality-of-life data meet, yet the real tension is between revenue guidance and ongoing losses. Get the fuller story with the 1 key reward and 1 important warning sign

Perimeter Medical Imaging AI (TSXV:PINK)

Overview: Perimeter Medical Imaging AI develops imaging systems that give surgeons real time, cross sectional views of excised tissue in the operating room, using its S Series OCT platform and Claire OCT with ImgAssist AI to help assess margins during breast conserving surgery. The company also supports hospitals and cancer centers with a proprietary image library and consumable specimen containers to build and use this data at the point of care.

Operations: Perimeter Medical Imaging AI generates about US$2.1 million in revenue from medical imaging systems, all from Canada.

Market Cap: CA$46.8 million

Perimeter Medical Imaging AI operates at the intersection of AI, imaging hardware, and unmet needs in breast conserving surgery, with Claire OCT cleared as an AI enabled intraoperative device trained on more than 2 million breast tissue images. A large discount to some fair value estimates has caught attention, yet current annual sales of roughly CA$2 million, ongoing losses, and high P/S multiples keep risk firmly on the table. Recent funding rounds and higher risk borrowing underline that balance sheet strength is still a key question. For investors looking at AI healthcare tools that may change surgical decision making, the key consideration is how quickly hospitals adopt these systems and whether that eventually supports more sustainable economics.

Perimeter Medical Imaging AI sits at the intersection of AI, imaging hardware, and surgical decision making, yet its small revenue base and high P/S raise big questions. To see how that balance of promise and pressure really stacks up, start with the 2 key rewards and 3 important warning signs (1 is major!)

The three stocks in this article are only a starting point, and the full Transformative Artificial intelligence (AI) Healthcare Stocks screener surfaced 4 more companies with equally compelling AI healthcare stories to review. Use Simply Wall St to identify the specific catalysts, risks, and narratives that matter to you so you can analyze these opportunities and focus on the highest conviction ideas.

Take Control of Your Investment Journey

If Telescope Innovations or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly

Some stocks are already building quiet momentum while most investors stay focused elsewhere. Before these ideas stop looking under the radar for now, scan these fresh shortlists.

• Spot strong balance sheets early and use the list of solid balance sheet and fundamentals (11 results) to filter for companies that pair resilience with fundamentals before the crowd catches on.
• Review structural shifts in payments and digital assets by checking the curated 19 cryptocurrency and blockchain stocks that highlight businesses positioned around blockchain and cryptocurrency themes.
• Explore the next wave in automation by reviewing the hand picked 34 robotics and automation stocks that focus on companies building robotics and industrial automation momentum.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com